CAPR vs RNA
CAPR: Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment. RNA: Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in the heart.
Side-by-side fundamentals
| Metric | CAPR | RNA | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $4.18 | $12.11 | |
| Market cap as of 2026-08-08 | $244M | $207M | |
| PEG as of 2026-08-08 | -0.03 | n/a | |
| Net margin as of 2026-08-08 | -181.7% | -172.9% | RNA higher |
| Operating margin as of 2026-08-08 | -191.1% | -174.9% | RNA higher |
| ROE as of 2026-08-08 | -59.3% | -40.3% | RNA higher |
| ROA as of 2026-08-08 | -48.6% | -592.6% | CAPR higher |
| Debt / equity as of 2026-08-08 | 0.02 | 0.00 | RNA lower |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +22.0% | |
| Beta as of 2026-08-08 | 0.27 | 1.05 | |
| 1-year return as of 2026-08-06 close | -46.0% | -74.9% | CAPR higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.